Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) EVP Neil Stahl Sells 4,006 Shares | 12/4/2019

… of the company’s stock, valued at approximately $11,815,891.85. The sale was disclosed in a filing with the SEC, which is available through this hyperlink . Neil Stahl also recently made the following trade(s): Get Regeneron Pharmaceuticals alerts: On Friday, November 8th, Neil Stahl sold 7,364 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $338.52, for a total transaction of $2,492,861.28. NASDAQ REGN traded up …

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Expected to Post Quarterly Sales of $2.10 Billion | Daily Political | 12/4/2019

Equities research analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will announce $2.10 billion in sales for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the highest sales estimate coming in at $2.22 billion and the lowest estimate coming in at $2.01 billion. Regeneron Pharmaceuticals posted sales of $1.93 billion in the same quarter last year, which would indicate a positive …

Follow Regeneron Pharmaceuticals:    

Analysts Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Announce Quarterly Sales of $2.10 Billion | 12/4/2019

Equities analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $2.10 billion in sales for the current quarter, Zacks reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.01 billion and the highest estimate coming in at $2.22 billion. Regeneron Pharmaceuticals reported sales of $1.93 billion in the same quarter last year, which would suggest a positive year over year …

Analysts Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Announce Quarterly Sales of $2.10 Billion - Ticker Report | 12/4/2019

Equities analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $2.10 billion in sales for the current quarter, Zacks reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.01 billion and the highest estimate coming in at $2.22 billion. Regeneron Pharmaceuticals reported sales of $1.93 billion in the same quarter last year, which would suggest a positive year over year …

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Given Average Recommendation of “Hold” by Brokerages - Ticker Report | 12/4/2019

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have received an average recommendation of “Hold” from the twenty-four research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts …

Insider Selling: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Sells 1,000 Shares of Stock - WKRB News | 12/4/2019

… transaction, the director now directly owns 11,323 shares of the company’s stock, valued at $4,189,510. The sale was disclosed in a document filed with the SEC, which is available through this link . Shares of Regeneron Pharmaceuticals stock opened at $368.81 on Wednesday. Regeneron Pharmaceuticals Inc has a fifty-two week low of $271.37 and a fifty-two week high of $442.00. The business’s fifty day moving average is $331.72 and …

Zacks: Brokerages Anticipate Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Announce Earnings of $6.83 Per Share | 12/3/2019

Equities research analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will report earnings per share of $6.83 for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $8.23 and the lowest estimate coming in at $5.18. Regeneron Pharmaceuticals posted earnings of $6.84 per share during the same quarter last year, which would indicate a negative year …

Analysts Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Post Earnings of $6.83 Per Share - TheOlympiaReport | 12/3/2019

Equities analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will announce earnings of $6.83 per share for the current quarter, according to Zacks Investment Research . Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings. The lowest EPS estimate is $5.18 and the highest is $8.23. Regeneron Pharmaceuticals reported earnings per share of $6.84 in the same quarter last year, which suggests a negative year-over-year growth rate of 0.1 …

Regeneron Pharmaceuticals continues East Greenbush expansion | 12/3/2019

… Union) Parking garage across from Regeneron Pharmaceuticals’ 10,000-square-foot addition on Tuesday, Nov. 3, 2019 in East Greenbush, N.Y. (Lori Van Buren/Times Union) Photo: Lori Van Buren, Albany Times Union Buy photo Regeneron Pharmaceuticals continues East Greenbush expansion 1 / 10 Back to Gallery EAST GREENBUSH – Regeneron Pharmaceuticals plans to expand at its 67.7-acre Red Mill Campus off Columbia Turnpike by adding a 10,000-plus square foot warehouse …

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Receives $384.63 Average Price Target from Brokerages | Daily Political | 12/3/2019

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have been assigned a consensus rating of “Hold” from the twenty-four research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts …

Virtu Financial LLC Sells 4,648 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 12/2/2019

Virtu Financial LLC Sells 4,648 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Posted by Martin Roberts on Dec 2nd, 2019 Virtu Financial LLC reduced its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 69.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,055 shares of the biopharmaceutical company’s stock after selling 4,648 shares during the period …

Global Angiopoietin 2 Market Data Analyis 2019-2024: : Amgen Inc., AnGes MG, Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company | 12/1/2019

Global Angiopoietin 2 Market Data Analyis 2019-2024: : Amgen Inc., AnGes MG, Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company 9 mins ago Ann.Castro The global “ Angiopoietin 2 Market “ report offers an orderly representation of the market by the combinations, methods, summarized study, and gathering data from various sources. The market report includes the complete seller-buyer scenario, along with a SWOT analysis of the key market players Amgen Inc., AnGes …

Reply | 12/1/2019

We thank Sharma et al for their interest in our article and the HAWK and HARRIER trials. 1 x 1 Dugel, P.U., Koh, A., Ogura, Y. et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology . 2019 Apr 12 ; ( pii: S0161-6420(18)33018-5. doi: 10.1016/j.ophtha.2019.04.017 . [Epub ahead of print]. ) Abstract Full Text Full Text PDF Scopus (15 …

National Pension Service Purchases 4,867 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 12/1/2019

National Pension Service increased its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 4.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 106,783 shares of the biopharmaceutical company’s stock after buying an additional 4,867 shares during the period. National Pension Service owned 0.10% of Regeneron Pharmaceuticals worth $29,622,000 at the end of the most …

Squarepoint Ops LLC Has $14.64 Million Stock Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 12/1/2019

Squarepoint Ops LLC reduced its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 8.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 52,787 shares of the biopharmaceutical company’s stock after selling 4,799 shares during the period. Squarepoint Ops LLC’s holdings in Regeneron Pharmaceuticals were worth $14,643,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors …

Public Employees Retirement System of Ohio Acquires 209 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 12/1/2019

Public Employees Retirement System of Ohio lifted its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 49,426 shares of the biopharmaceutical company’s stock after acquiring an additional 209 shares during the period. Public Employees Retirement System of Ohio’s holdings in Regeneron Pharmaceuticals were worth $13,711,000 at …

Public Employees Retirement System of Ohio Buys 209 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | Daily Political | 12/1/2019

Public Employees Retirement System of Ohio lifted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,426 shares of the biopharmaceutical company’s stock after purchasing an additional 209 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Regeneron Pharmaceuticals were worth $13,711,000 as …

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by BidaskClub - Dakota Financial News | 12/1/2019

BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research note published on Wednesday, BidAskClub reports. Several other analysts also recently weighed in on REGN. Cowen set a $349.00 target price on shares of Regeneron Pharmaceuticals and gave the company a hold rating in a report on Tuesday, October 8th. SunTrust Banks assumed coverage on shares of Regeneron Pharmaceuticals in a …

Orbimed Advisors LLC Increases Stock Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - TheOlympiaReport | 11/30/2019

Orbimed Advisors LLC increased its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 5.7% in the 3rd its most recent disclosure with the Securities and Exchange Commission. The firm owned 228,100 shares of the biopharmaceutical company’s stock after purchasing an additional 12,300 shares during the quarter. Orbimed Advisors LLC owned 0.21% of Regeneron Pharmaceuticals worth $63,275,000 as of its most recent filing with the Securities and Exchange Commission. Several other …

PointState Capital LP Invests $3.94 Million in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 11/30/2019

PointState Capital LP purchased a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 14,200 shares of the biopharmaceutical company’s stock, valued at approximately $3,939,000. A number of other institutional investors have also recently made changes to their positions in REGN. Bank of Nova Scotia boosted its stake in …

Biotech

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

… them from pipeline. Companies Mentioned A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics SA Aduro BioTech Inc Affimed GmbH Agios Pharmaceuticals Inc AlfaSigma SpA Alissa Pharma Angiocrine Bioscience Inc Anhui … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… them from pipeline. Companies Mentioned A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics SA Aduro BioTech Inc Affimed GmbH Agios Pharmaceuticals Inc AlfaSigma SpA Alissa Pharma Angiocrine Bioscience Inc Anhui … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

National Institutes of Health

Investigational Drugs Reduce Risk of Death from Ebola Virus Disease | 12/4/2019

… Research (INRB) and Ministry of Health, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. Professor Jean-Jacques Muyembe-Tamfum, M.D., Ph.D., director-general of the … Mapp Biopharmaceutical; REGN-EB3, a monoclonal antibody cocktail developed by Regeneron Pharmaceuticals, Inc.; and remdesivir, an antiviral drug developed by Gilead Sciences, Inc. The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S …

Department of Health and Human Services

Investigational Drugs Reduce Risk of Death from Ebola Virus Disease | 12/4/2019

… Regeneron Pharmaceuticals, Inc.; and remdesivir, an antiviral drug developed by Gilead Sciences, Inc. The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also has provided support for the development of REGN-EB3, ZMapp and mAb114. The four therapies are administered as intravenous infusions. REGN-EB3 and mAb114 are administered as single infusions and ZMapp and remdesivir are administered as infusions over …

NIH

Investigational drugs reduce risk of death from Ebola virus disease | 12/3/2019

… Center and the INRB and licensed to Ridgeback Biotherapeutics and Mapp Biopharmaceutical; REGN-EB3, a monoclonal antibody cocktail developed by Regeneron Pharmaceuticals, Inc.; and remdesivir, an antiviral drug developed by Gilead Sciences, Inc. The Biomedical … for their participation and exceptional commitment to the trial.” (Fuente: NIH/National Institute of Allergy and Infectious Diseases) Copyright © 1996-2019 Amazings® / NCYT® (Noticiasdelaciencia.com / Amazings.com). Todos los derechos reservados. Depósito Legal B-47398-2009, ISSN 2013-6714 - Amazings …

National Cancer Institute

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) | 12/2/2019

… INO-9012, an immune activator encoding IL-12, in combination with Libtayo ® (cemiplimab), a PD-1 blocking antibody developed by Regeneron Pharmaceuticals (NASDAQ: REGN) in collaboration with Sanofi. Key interim data from the 52-patient … a powerful cancer immunotherapy in combination with checkpoint inhibitors. The National Cancer Institute previously highlighted hTERT, WT1, and PSMA among a list of important cancer antigens, designating them as high priorities for cancer immunotherapy development …

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Medical Research

Investigational drugs reduce risk of death from Ebola virus disease | 12/2/2019

… research consortium coordinated by the World Health Organization (WHO). It is led and funded by the DRC’s National Institute for Biomedical Research (INRB) and Ministry of Health, and the National Institute of Allergy and Infectious … Mapp Biopharmaceutical; REGN-EB3, a monoclonal antibody cocktail developed by Regeneron Pharmaceuticals, Inc.; and remdesivir, an antiviral drug developed by Gilead Sciences, Inc. The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S …

Food and Drug Administration

Re: Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration (Ophthalmology. 2019 Apr 12 [Epub ahead of print]) | 12/1/2019

Food and Drug Administration approval for q12w dosing, it would help readers if the authors could elaborate on the rationale of choosing strict q8w regime for aflibercept in a comparative trial. 2 x 2 Regeneron Pharmaceuticals Inc. FDA approves EYLEA® (aflibercept) injection sBLA in wet age-related macular degeneration. ( Available: ) https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-sbla-wet-age-related . Google Scholar See all …

Reply | 12/1/2019

… Regeneron Pharmaceuticals, Inc , Tarrytown, NY ; 2014 Google Scholar See all References The aflibercept dosing every 12 weeks (q12w) regimen after 1 year of dosing every 8 weeks (q8w) therapy was approved by the US Food and Drug Administration in mid-2018 (i.e., after completion of HAWK and HARRIER). Brolucizumab is the first anti-vascular endothelial growth factor agent to demonstrate that 50% of patients were successfully maintained on exclusively q12w …

Clinical Data

New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron’s REGN-EB3 to ZMapp in Preventing Ebola Deaths – Company Announcement - FT.com | Financial Times | 11/28/2019

… REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3 Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN) announced today that the New England Journal of Medicine (NEJM … an Ad-Hoc Expert Consultation to assess all preclinical and clinical data on available investigational products, and recommended the addition of REGN-EB3 as a fourth treatment arm. The National Institutes of Health (NIH) and …

Medicare

New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron’s REGN-EB3 to ZMapp in Preventing Ebola Deaths – Company Announcement - FT.com | Financial Times | 11/28/2019

… REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3 Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN) announced today that the New England Journal of Medicine (NEJM … organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid ; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; ongoing regulatory obligations and oversight impacting …

Medicaid

New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron’s REGN-EB3 to ZMapp in Preventing Ebola Deaths – Company Announcement - FT.com | Financial Times | 11/28/2019

… REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3 Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN) announced today that the New England Journal of Medicine (NEJM … benefit management companies, and government programs such as Medicare and Medicaid ; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; ongoing regulatory obligations and oversight impacting Regeneron’s marketed …

Novartis

Diabetic Retinopathy Market expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% | Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche | 12/4/2019

Novartis International AG, Pfizer, Regeneron Pharmaceuticals Inc., Valeant Pharmaceutical, Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., ThromboGenics NV Get sample copy of “Diabetic Retinopathy Market” at: https://www.premiummarketinsights.com/sample/AMR00013203 The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant …

Visiongain Report Claims There is Huge Potential Within the $39bn Dermatological Drugs Market | PR Newswire | 11/29/2019

… Myers Squibb • Celgene Corporation • Eli Lilly • Galderma (Nestle Skin Health S.A.) • GlaxoSmithKline (GSK) • Johnson & Johnson • LEO Pharma • Merck & Co, Inc. • Novartis • Pfizer • Key questions answered by this report: • How is the dermatological drugs market evolving … Pfizer PharmaPraxis Photocure Pierre Fabre Provectus Biopharmaceuticals QLT Inc Ranbaxy Regeneron Pharmaceuticals Roche Samsung Bioepis Samsung BioLogics Sandoz Sanofi Schering-Plough Shanghai CP Buojian Pharmaceutical Sidmak Labs Sol-Gel Technologies Ltd Sun Pharma Sunovion Takeda …

Pfizer

Diabetic Retinopathy Market expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% | Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche | 12/4/2019

… Pfizer, Regeneron Pharmaceuticals Inc., Valeant Pharmaceutical, Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., ThromboGenics NV Get sample copy of “Diabetic Retinopathy Market” at: https://www.premiummarketinsights.com/sample/AMR00013203 The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant growth during the …

Global Angina Pectoris Treatment Market Is Expected To Reach USD 12,589.6 Mn by 2022 | Credence Research | 12/3/2019

… Pfizer, Inc.), and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the largest market globally due to factors such as Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris. Pipeline Analysis The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka …

Merck

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Miltenyi Biotec GmbH NantKwest Inc NBE-Therapeutics AG NewBio Therapeutics Inc Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shanghai Junshi Bioscience Co Ltd Shanghai Pharmaceutical Group Co Ltd Shanghai Unicar-Therapy Bio-Medicine Technology …

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Miltenyi Biotec GmbH NantKwest Inc NBE-Therapeutics AG NewBio Therapeutics Inc Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shanghai Junshi Bioscience Co Ltd Shanghai Pharmaceutical Group Co Ltd Shanghai Unicar-Therapy Bio-Medicine Technology …

Celgene

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

… Ltd Avipep Pty Ltd BeiGene Ltd Biohaven Pharmaceutical Holding Company Ltd Bristol-Myers Squibb Co Carrick Therapeutics Ltd Catalent Inc Celgene Corp Cell Medica Ltd Celldex Therapeutics Inc Cellectar Biosciences Inc Cellectis SA Celleron Therapeutics … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… Ltd Avipep Pty Ltd BeiGene Ltd Biohaven Pharmaceutical Holding Company Ltd Bristol-Myers Squibb Co Carrick Therapeutics Ltd Catalent Inc Celgene Corp Cell Medica Ltd Celldex Therapeutics Inc Cellectar Biosciences Inc Cellectis SA Celleron Therapeutics … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

Allergan

Diabetic Retinopathy Market expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% | Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche | 12/4/2019

… Diabetic Retinopathy Market expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche The report on “Diabetic Retinopathy … Bayer AG, F. Hoffmann-La Roche, Novartis International AG, Pfizer, Regeneron Pharmaceuticals Inc., Valeant Pharmaceutical, Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., ThromboGenics NV Get sample copy of “Diabetic Retinopathy Market” at: https …

Diabetic Retinopathy Market Overview up to 2027 – Abbott Laboratories, Alimera Science, Allergan Plc, Ampio Pharmaceuticals. | 12/3/2019

Press Releases Diabetic Retinopathy Market Overview up to 2027 – Abbott Laboratories, Alimera Science, Allergan Plc, Ampio Pharmaceuticals. The latest addition of Diabetic Retinopathy Market 2027 to The Insight Partners’ store offers major insights on the … growth of the market during the forecast period. Key Players: - Regeneron Pharmaceuticals Inc - Valeant Pharmaceutical The “Global Diabetic Retinopathy Market Analysis to 2027” is a specialized and in-depth study of the medical devices industry …

Gilead Sciences

Investigational Drugs Reduce Risk of Death from Ebola Virus Disease | 12/4/2019

… Regeneron Pharmaceuticals, Inc.; and remdesivir, an antiviral drug developed by Gilead Sciences, Inc. The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also has provided support for the development of REGN-EB3, ZMapp and mAb114. The four therapies are administered as intravenous infusions. REGN-EB3 and mAb114 are administered as single infusions and ZMapp and remdesivir are administered as infusions over …

Bristol-Myers Squibb

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

… Inc Astellas Pharma Inc AstraZeneca Plc Aurigene Discovery Technologies Ltd Avipep Pty Ltd BeiGene Ltd Biohaven Pharmaceutical Holding Company Ltd Bristol-Myers Squibb Co Carrick Therapeutics Ltd Catalent Inc Celgene Corp Cell Medica Ltd Celldex … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… Inc Astellas Pharma Inc AstraZeneca Plc Aurigene Discovery Technologies Ltd Avipep Pty Ltd BeiGene Ltd Biohaven Pharmaceutical Holding Company Ltd Bristol-Myers Squibb Co Carrick Therapeutics Ltd Catalent Inc Celgene Corp Cell Medica Ltd Celldex … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

AbbVie

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

… projects and understand from the know-how what drove them from pipeline. Companies Mentioned A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics SA Aduro BioTech Inc Affimed GmbH Agios Pharmaceuticals … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

… projects and understand from the know-how what drove them from pipeline. Companies Mentioned A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics SA Aduro BioTech Inc Affimed GmbH Agios Pharmaceuticals … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

Incyte

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

Incyte Corp Inhibrx Inc Kite Pharma Inc Magenta Therapeutics Inc Marker Therapeutics Inc Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Miltenyi Biotec GmbH NantKwest Inc NBE-Therapeutics AG NewBio Therapeutics Inc Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shanghai Junshi Bioscience …

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

Incyte Corp Inhibrx Inc Kite Pharma Inc Magenta Therapeutics Inc Marker Therapeutics Inc Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Miltenyi Biotec GmbH NantKwest Inc NBE-Therapeutics AG NewBio Therapeutics Inc Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shanghai Junshi Bioscience …

Boehringer Ingelheim

Diabetic Retinopathy Market expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% | Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche | 12/4/2019

Regeneron Pharmaceuticals Inc., Valeant Pharmaceutical, Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., ThromboGenics NV Get sample copy of “Diabetic Retinopathy Market” at: https://www.premiummarketinsights.com/sample/AMR00013203 The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant growth during the forecast …

Global Angiopoietin 2 Market Data Analyis 2019-2024: : Amgen Inc., AnGes MG, Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company | 12/1/2019

Global Angiopoietin 2 Market Data Analyis 2019-2024: : Amgen Inc., AnGes MG, Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company 9 mins ago Ann.Castro The global “ Angiopoietin 2 Market “ report offers an orderly representation of the … Lilly and Company, F. Hoffmann-La Roche Ltd., MedImmune, LLC, Regeneron Pharmaceuticals, Inc., RXi Pharmaceuticals Corporation, Silence Therapeutics Plc, Synergys Biotherapeutics, Inc.. Consequently, the information provided through the report is reliable, wide-ranging, and the …

Citigroup

Analysts Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Announce Quarterly Sales of $2.10 Billion | 12/4/2019

Equities analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $2.10 billion in sales for the current quarter, Zacks reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with the lowest sales estimate … the company in a research note on Monday, November 11th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $340.00 to …

Analysts Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Announce Quarterly Sales of $2.10 Billion - Ticker Report | 12/4/2019

Equities analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $2.10 billion in sales for the current quarter, Zacks reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with the lowest sales estimate … the company in a research note on Monday, November 11th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $340.00 to …

SunTrust Bank

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) EVP Neil Stahl Sells 4,006 Shares | 12/4/2019

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) EVP Neil Stahl Sells 4,006 Shares Posted by Jennifer Kim on Dec 3rd, 2019 Tweet Regeneron Pharmaceuticals Inc (NASDAQ:REGN) EVP Neil Stahl sold 4,006 shares of the stock in … perform” rating in a report on Wednesday, November 6th. Finally, SunTrust Banks initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, November 12th. They set a “hold” rating and a $360.00 …

Insider Selling: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Sells 1,000 Shares of Stock - WKRB News | 12/4/2019

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the firm’s that occurred on Wednesday, November 27th. The stock was sold at an average price of $370.00, for a total transaction … the company in a report on Wednesday, August 7th. Finally, SunTrust Banks initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, November 12th. They issued a “hold” rating and a $360.00 price objective …

Morgan Stanley

🌎 Nutanix Sold, Beyond Meat Sold, Brookline Bancorp Sold and more… | 12/3/2019

… for Netflix Stock My Top Marijuana Pick Is Booming (Ad) Cyber Monday; Who Will Be Crowned King Of The Internet Morgan Stanley Slaps Roku With Downgrade After Massive Rally How Level II Quotes Can Transform … Sell 3,750 shares @ $29.00 $108,750.00 11/27/2019 View $28.60 Read More Regeneron Pharmaceuticals ( NASDAQ:REGN ) Joseph L Goldstein (Director) Sell 1,000 shares @ $370.00 $370,000.00 11/27/2019 View $366.37 Read More Reinsurance Group of America ( NYSE:RGA ) John …

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Receives Consensus Recommendation of “Hold” from Analysts | 11/26/2019

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been given an average rating of “Hold” by the twenty-four research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with … been the topic of a number of recent analyst reports. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $375.00 to $387.00 and gave the stock an “equal weight” rating in a research report …

OrbiMed Advisors

Orbimed Advisors LLC Increases Stock Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - TheOlympiaReport | 11/30/2019

Orbimed Advisors LLC increased its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 5.7% in the 3rd its most recent disclosure with the Securities and Exchange Commission. The firm owned 228,100 shares of the biopharmaceutical company’s stock after purchasing an additional 12,300 shares during the quarter. Orbimed Advisors LLC owned 0.21% of Regeneron Pharmaceuticals worth $63,275,000 as of its most recent filing with the Securities and Exchange Commission. Several other …

Mackenzie Financial Corp Sells 5,851 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 10/13/2019

Mackenzie Financial Corp Sells 5,851 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Posted by Kristine Brawn on Oct 13th, 2019 Tweet Mackenzie Financial Corp reduced its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 85.9 … after buying an additional 940 shares during the last quarter. Orbimed Advisors LLC raised its stake in Regeneron Pharmaceuticals by 0.5% during the 2nd quarter. Orbimed Advisors LLC now owns 215,800 shares of the biopharmaceutical …

Goldman Sachs

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma Genesis Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | Markets Insider | Business Insider | 11/27/2019

… F-Prime Capital GeneCopoeia GeneCust GeneDesign GENEL Genentech GenePharma Genesis Pharmaceuticals Sanofi Genzyme / Genzyme Genomics England GlaxoSmithKline (GSK) Glycostem Therapeutics Goldman Sachs Gradalis Gritstone Oncology Guang’anmen Hospital of China Academy of Chinese Medical Sciences Harvard … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

SVB Leerink

Benzinga’s Top Upgrades, Downgrades For November 7, 2019 | 11/7/2019

… high of $13.52 and a 52-week-low of $6.92. Quotient Technology’s stock last closed at $9.53 per share. For Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), Citigroup upgraded the stock from Neutral to Buy. Regeneron Pharmaceuticals … 6.34. Antero Midstream’s stock last closed at $6.83 per share. SVB Leerink changed the rating for Amneal Pharmaceuticals Inc (NYSE: AMRX ) from Outperform to Market Perform. For the third quarter, Amneal Pharmaceuticals had an EPS …

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/6/2019

… source: The Motley Fool. Nov 05, 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Good morning, and welcome to the Regeneron Pharmaceuticals third-quarter 2019 earnings conference call. My name is Sheryl, and I will … next question comes from George – I’m sorry, Geoff Porges from SVB Leerink. Geoff Porges – SVB Leerink – Analyst Thank you very much for taking my question. A quick question. You have three products that are – look …

Jefferies Financial Group

Investment Analysts’ Price Target Changes for November, 6th (ABBN, ADS, BMW, BNR, BOSS, CC, DTE, DVA, EVK, FRA) | 11/6/2019

… neutral rating on the stock. Bayerische Motoren Werke (ETR:BMW) was given a €70.00 ($81.40) price target by analysts at Jefferies Financial Group Inc. The firm currently has a neutral rating on the stock. Bayerische … Leerink Swann currently has an outperform rating on the stock. Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by BMO Capital Markets to $358.00. They currently have a market perform rating on the stock …

🌎 Datadog Initiated, Centurylink Downgraded, Autohome Downgraded and more… | 11/6/2019

… the stock. 24.3% downside from the current price of $13.22. Read More . Daicel ( OTCMKTS:DACHF ) was downgraded by analysts at Jefferies Financial Group Inc from a “buy” rating to a “hold” rating. Read More . Daimler … 48.6% upside from the current price of $23.55. Read More . Regeneron Pharmaceuticals ( NASDAQ:REGN ) had its price target raised by analysts at BMO Capital Markets to $358.00. They now have a “market perform” rating on …

BlackRock Inc.

BlackRock Inc. Raises Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - WKRB News | 11/6/2019

BlackRock Inc. lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.0% in the 2nd quarter, according to the company in its most recent 13F filing Commission. The fund owned 6,045,652 shares of the biopharmaceutical company’s stock 2,744 shares during the period. BlackRock Inc. owned 5.50% of Regeneron Pharmaceuticals worth $1,892,289,000 at the end of the most recent quarter. Other hedge funds also recently modified their holdings …

Asset Management One Co. Ltd. Sells 8,748 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 10/3/2019

Asset Management One Co. Ltd. lessened its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 16.5% during the second quarter, according to the company in its most recent filing with the Securities and … investors also recently bought and sold shares of the business. BlackRock Inc. increased its stake in Regeneron Pharmaceuticals by 1.9% during the 1st quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock …

Merrill Lynch

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/6/2019

… source: The Motley Fool. Nov 05, 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Good morning, and welcome to the Regeneron Pharmaceuticals third-quarter 2019 earnings conference call. My name is Sheryl, and I will … Your line is now open. Geoff Meacham – Bank of America Merrill Lynch – Analyst Thanks for the question. Just have a couple for Bob. I wanted to ask about the commercialization-related expenses. Was this just …

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/5/2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Justin Holko - VP, IR Len Schleifer - Co-Founder, President & CEO George Yancopoulos - Founding Scientist, President, Chief Scientific Officer & Director Marion McCourt - SVP & Head, Commercial Robert Landry - EVP, Finance & CFO Conference Call Participants Christopher Raymond - Piper Jaffray Companies Aaron Gal - Sanford C. Bernstein & Co. Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Porges …

Sterling Capital Management

Sterling Capital Management LLC Sells 15,901 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 9/22/2019

Sterling Capital Management LLC decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 92.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 1,316 shares of the biopharmaceutical company’s stock after selling 15,901 shares during the period. Sterling Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $412,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds also …

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Sold by Sterling Capital Management LLC | 9/22/2019

Sterling Capital Management LLC trimmed its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 92.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,316 shares of the biopharmaceutical company’s stock after selling 15,901 shares during the period. Sterling Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $412,000 at the end of the most recent reporting period. Other …

University of Texas MD Anderson Cancer Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | The Wapakoneta Daily News | 11/28/2019

… Therapeutics Promab Biotechnologies Promega Promethera Biosciences Protheragen PsiOxus Therapeutics PTC Therapeutics Purdue University Qingdao Central Hospital Quethera Recombinetics Refuge Biotechnologies Regeneron Pharmaceuticals REGENXBIO RenJi Hospital Renova Therapeutics Rentschler Biopharma Repare Therapeutics ReproCELL RetroSense Therapeutics Reyon … University of Pennsylvania University of Southern California University of Technology University of Texas MD Anderson Cancer Center University of Zurich Unum Therapeutics Uppsala University Urovant Sciences UT Southwestern Medical Center V Foundation ValueAct Capital Management …

University of Texas Southwestern Medical Center

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | PR Newswire | 11/22/2019

TARRYTOWN, N.Y. Columbia’s highest honor bestowed for Yancopoulos’ contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded … Regental Professor of Molecular Genetics and Internal Medicine at the University of Texas Southwestern Medical Center . Biography & Career Accomplishments Yancopoulos, the son of Greek immigrants and a life-long New Yorker, attended New York City …

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | BioSpace | 11/22/2019

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award Published: Nov 22, 2019 TARRYTOWN, N.Y. , Nov. 22, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. , (NASDAQ: REGN) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and … Regental Professor of Molecular Genetics and Internal Medicine at the University of Texas Southwestern Medical Center . Biography & Career Accomplishments Yancopoulos, the son of Greek immigrants and a life-long New Yorker, attended New York City …

Mayo Clinic

Mayo Clinic in the News Weekly Highlights for November 8, 2019 | 11/8/2019

Mayo Clinic in the News Weekly Highlights for November 8, 2019 By Emily Blahnik Editors: Emily Blahnik , Karl Oestreich Quartz , Rare genetic mutations protected a woman from developing Alzheimer’s by Katherine Ellen Foley — This case … Russell, announced “a strategic research collaboration” with Tarrytown, N.Y.-based Regeneron Pharmaceuticals this morning. “It is transformative for the company,” Russell said of the Regeneron deal. “It puts us on track to do everything we …

Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer | PR Newswire | 11/6/2019

… V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Vyriad, Inc. today announced a research collaboration and option … of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami , Vyriad programs viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process …

HCA

WRL for Nov 2 | 11/2/2019

… 136.93 129.38 3.81 ▼ 37 17.24% Paypal PYPL 104.98 107.74 -2.50 ▲ 5 -1.83% QUALCOMM Inc QCOM 83.58 73.74 2.22 ▲ 30 44.63% Regeneron Pharmaceuticals REGN 310.48 319.68 -0.55 ▲ 28 6.62% Ross Stores Inc ROST 110.99 104.28 3.35 … Calamos Strategic TR Fund CSQ 13.05 12.51 0.68 ▲ 19 2.11% Healthcare Bull 3X ETF CURE 58.41 50.20 0.10 ▲ 0 0.00% Buy DB Agriculture ETF DBA 16.07 15.61 0.90 ▲ 2 0.88% DB Commodity Tracking ETF DBC …

Fibrogen names James A. Schoeneck interim CEO | MarketWatch | 8/26/2019

HCA Healthcare Inc, Regeneron Pharmaceuticals Inc, Sells Horizon Therapeutics PLC, Array BioPharma Inc, Allergan PLC Jul. 22, 2019 at 7:38 p.m. ET on GuruFocus.com Late-stage study underway for FibroGen’s pamrevlumab in IPF Jul. 22, 2019 at 8:42 Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares Jul. 12, 2019 at 5:15 p.m. ET on GuruFocus.com FibroGen (FGEN) Investor Presentation - Slideshow Jun. 12, 2019 at 3:14 Fibrogen …

Tenet Healthcare

WRL for Nov 2 | 11/2/2019

… 136.93 129.38 3.81 ▼ 37 17.24% Paypal PYPL 104.98 107.74 -2.50 ▲ 5 -1.83% QUALCOMM Inc QCOM 83.58 73.74 2.22 ▲ 30 44.63% Regeneron Pharmaceuticals REGN 310.48 319.68 -0.55 ▲ 28 6.62% Ross Stores Inc ROST 110.99 104.28 3.35 … 1 -2.55% TEGNA Inc TGNA 15.23 14.55 0.88 ▲ 8 -4.03% Tenet Healthcare THC 25.88 21.35 2.43 ▲ 7 3.69% Hanover Insurance Group THG 129.59 127.40 1.72 ▼ 37 10.25% Thor Industries Inc THO 65.14 53.35 3.22 ▲ 2 …

Disney Headlines Upcoming Earnings Slate | 10/31/2019

… FN), Ferrari (RACE), Groupon (GRPN), Hertz (HTZ), Marriott (MAR), RingCentral (RNG) , SHAK, Sprint (S), Sysco (SYY), Tandem Diabetes Care (TNDM) , Tenet Healthcare (THC), UBER, and Under Armour (UAA) will report earnings. For Tuesday, Nov. 5 … Newmont Mining (NEM), Peloton (PTON), Red Robin Gourmet Burgers (RRGB), Regeneron Pharmaceuticals (REGN), Tapestry (TPR), Trivago (TRVG), Whiting Petroleum (WLL), and WW (WW) make up the earnings slate. Productivity and labor costs and weekly crude …

MD Anderson Cancer Center

Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019 | Globe Newswire | 10/30/2019

MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals. Ziopharm Contact: VP, Investor Relations and Corporate Communications 617-502-1881 …

Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019 | Financial Buzz | 10/30/2019

MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals. Ziopharm Contact: Chris Taylor VP, Investor Relations and Corporate Communications 617-502-1881 [email protected]

Memorial Sloan Kettering

Novel Cell Sorting and Separation Markets, 2030 | PR Newswire | 10/7/2019

… Lupin Mackay Memorial Hospital Massachusetts Institute of Technology Mayo Clinic Foundation MD Anderson Cancer Center MDxK Medigen Biotech MeMed Diagnostics Memorial Sloan Kettering Cancer Center Menarini Silicon Biosystems Merck Metabiota Microbix Biosystems MicroMedicine Middle East … Quad Technologies Qventures R&D Systems RareCyte Real Tech Fund Regeneron Pharmaceuticals Regionalt Cancercentrum Stockholm-Gotland RIKEN Bioresource Research Center Riverside’s Highlander Venture Fund Roche Roswell Park Comprehensive Cancer Center Rowan University Rush University Medical …

Global Neoantigen Targeted Therapies Market 2019-2030: Marketed and Development Pipeline, Pipeline Analysis, List of Drug Developers | PR Newswire | 8/6/2019

… Therapeutics Max Delbrck Center for Molecular Medicine in the Helmholtz Association MD Anderson Cancer Center Medigene MedImmune Meir Medical Center Memorial Sloan Kettering Cancer Center Merck Meusinvest Mie University Miller Value Partners Miracle Light Incubator … Precision BioLogic ProBioGen Quogue Capital RA Capital Management Redmile Group Regeneron Pharmaceuticals Replimune Roche RTW Investments Ruffer Rutgers Cancer Institute Sailing Capital Sanquin Blood Supply Foundation Sant Ventures Schroder Adveq SciVac Therapeutics Sectoral Asset Management …

HCA Healthcare

Fibrogen names James A. Schoeneck interim CEO | MarketWatch | 8/26/2019

HCA Healthcare Inc, Regeneron Pharmaceuticals Inc, Sells Horizon Therapeutics PLC, Array BioPharma Inc, Allergan PLC Jul. 22, 2019 at 7:38 p.m. ET on GuruFocus.com Late-stage study underway for FibroGen’s pamrevlumab in IPF Jul. 22, 2019 at 8:42 Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares Jul. 12, 2019 at 5:15 p.m. ET on GuruFocus.com FibroGen (FGEN) Investor Presentation - Slideshow Jun. 12, 2019 at 3:14 Fibrogen …

Argus Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold | 7/12/2019

Argus Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold Posted by Charles Blunt on Jul 11th, 2019 Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by research analysts at Argus from a “buy” rating to a “hold” rating … Financial Group set a $158.00 price objective on shares of HCA Healthcare and gave the stock a “buy” rating in a report on Wednesday, April 17th. Three analysts have rated the stock with a sell …

Humana

🌎 The Week Ahead for 11/3/2019 | 11/3/2019

… Technology Inc. ( MCHP ), Newmont Goldcorp Corp ( NEM ), PetroChina Company Limited ( PTR ), Plains All American Pipeline, L.P. ( PAA ), PPL Corp ( PPL ), Regeneron Pharmaceuticals Inc ( REGN ), SK Telecom Co Ltd ( SKM ), Telefonica Brasil SA ( VIV ), Telefonica S.A … FOX ), Fox Corp ( FOXA ), Godaddy Inc ( GDDY ), Hologic, Inc. ( HOLX ), Humana Inc ( HUM ), IAC/InterActiveCorp ( IAC ), IQIYI Inc ( IQ ), Liberty Global PLC ( LBTYA ), Liberty Global PLC ( LBTYB ), Liberty Global PLC ( LBTYK ), Manulife Financial Co. ( MFC …

Holiday Shopping Starts Earler Than Usual - Barron’s | 11/2/2019

… hosts an analyst meeting in Los Angeles. Tuesday 11/5 Becton Dickinson , Emerson Electric , Fidelity National Information Services , Newmont Goldcorp, and Regeneron Pharmaceuticals report earnings. It’s Election Day across much of the U.S. This off-year … August. Wednesday 11/6 Barrick Gold, CVS Health , EOG Resources , Fiserv, Humana, Qualcomm , and Square report quarterly results. Phillips 66 hosts an analyst and investor day in New York City. The BLS reports productivity and costs …

Cigna

WRL for Nov 2 | 11/2/2019

… 136.93 129.38 3.81 ▼ 37 17.24% Paypal PYPL 104.98 107.74 -2.50 ▲ 5 -1.83% QUALCOMM Inc QCOM 83.58 73.74 2.22 ▲ 30 44.63% Regeneron Pharmaceuticals REGN 310.48 319.68 -0.55 ▲ 28 6.62% Ross Stores Inc ROST 110.99 104.28 3.35 … CH Robinson Worldwide CHRW 74.70 87.25 0.52 ▼ 0 0.00% Sell Cigna Corp CI 179.51 158.30 0.52 ▲ 1 4.56% Cincinnati Financial CINF 112.10 103.74 4.93 ▼ 66 50.35% Colgate-Palmolive Co CL 66.81 72.25 -3.03 ▼ 2 1.75 …

Pinduoduo stock price target raised to $39 from $28 at Benchmark | MarketWatch | 8/22/2019

… For August 21, 2019 Aug. 21, 2019 at 3:19 a.m. ET on benzinga.com Nordea Investment Management Ab Buys Alphabet Inc, Cigna Corp, W.W. Grainger Inc, Sells Banco De Chile, Alphabet Inc, The Walt Disney Co … Rong (HK) Asset Management Ltd Buys Advanced Micro Devices Inc, Regeneron Pharmaceuticals Inc, Microsoft Corp, Sells Alibaba Group Holding, Apple Inc, SPDR Gold Trust Aug. 13, 2019 at 4:38 p.m. ET on GuruFocus.com Thinking about …

Aetna

Health care is one of the stock market’s healthiest sectors right now - MarketWatch | 7/8/2019

… Surgical Inc. ISRG, -0.76% $1,032 $909 13% $8.94 $7.67 16% ResMed Inc. RMD, -0.42% $700 $624 12% $4.88 $4.33 13% Regeneron Pharmaceuticals Inc. REGN, -1.36% $1,803 $1,608 12% $16.45 $14.05 17% Alexion Pharmaceuticals Inc. ALXN … You can see that for CVS CVS, -0.47% which acquired Aetna in November, the company’s shares were diluted significantly. Second-quarter revenue is expected to increase by 34% from a year earlier, but sales per …

Regeneron Pharmaceuticals (REGN) Q3 2017 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2017

Regeneron Pharmaceuticals (REGN) Q3 2017 Results - Earnings Call Transcript Nov. 8.17 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q3 2017 Earnings Call November 08, 2017 8:30 am ET Executives Manisha Narasimhan, Ph.D. - Regeneron Pharmaceuticals, Inc. Leonard S … Scripts and CVS, Dupixent is also on formulary at Optum, Aetna, Anthem, and United. In the coming weeks, we’ll be launching unbranded direct-to-consumer television advertising to increase awareness of moderate to severe atopic …

Melinda Gates

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) | 12/2/2019

… INO-9012, an immune activator encoding IL-12, in combination with Libtayo ® (cemiplimab), a PD-1 blocking antibody developed by Regeneron Pharmaceuticals (NASDAQ: REGN) in collaboration with Sanofi. Key interim data from the 52-patient … HIV. Partners and collaborators include ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium …

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | The Wapakoneta Daily News | 11/28/2019

… Hospital Beijing Mario Biotech Beijing Sanbo Brain Hospital Beijing Sanwater Biological Technology Bellicum Pharmaceuticals Benchling Berlin Institute of Health Bill & Melinda Gates Foundation BioAtla BioCat Bioceltech Therapeutics BioChain Biocodon Technologies Biocytogen Biogen BioInvent Biolegio Biologics … Therapeutics Purdue University Qingdao Central Hospital Quethera Recombinetics Refuge Biotechnologies Regeneron Pharmaceuticals REGENXBIO RenJi Hospital Renova Therapeutics Rentschler Biopharma Repare Therapeutics ReproCELL RetroSense Therapeutics Reyon Pharmaceutical Roche Rocket Pharmaceuticals Rockland Immunochemicals Roger Williams Medical Center …

Sara Peerun

Visiongain Report Claims There is Huge Potential Within the $39bn Dermatological Drugs Market | PR Newswire | 11/29/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/dermatological-drugs … Pfizer PharmaPraxis Photocure Pierre Fabre Provectus Biopharmaceuticals QLT Inc Ranbaxy Regeneron Pharmaceuticals Roche Samsung Bioepis Samsung BioLogics Sandoz Sanofi Schering-Plough Shanghai CP Buojian Pharmaceutical Sidmak Labs Sol-Gel Technologies Ltd Sun Pharma Sunovion Takeda …

Visiongain Report Looks at Opportunities Within the $257bn Rare Disease Drugs Market | PR Newswire | 10/7/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-rare … Pharmaceuticals PTC Therapeutics QLT Quest PharmaTech Qurient Raptor Pharmaceutical Rebiotx Regeneron Pharmaceuticals Regulus Therapeutics & Sanofi US Retrophin RetroSense Therapeutics ReveraGen Biopharma Rexahn Pharmaceuticals Rhythm Metabolics Rigel Pharmaceuticals River Vision Roche Sanofi S. A. Santhera Pharmaceuticals …

Anthony Fauci

Two Ebola treatments yield ‘substantial decrease’ in mortality, landmark trial shows | STAT | 11/28/2019

Regeneron Pharmaceuticals ( REGN ) and a single monoclonal antibody developed by the National Institute for Allergy and Infectious Diseases called mAb114 succumbed to their infections. The overall mortality rate in the outbreak, which enters its 17th month next week, stands at 67%. advertisement “It was a substantial decrease [in mortality],’’ said Dr. Anthony Fauci, director of NIAID, which designed and helped conduct the trial. “When you look at people who have …

Two Ebola treatments yield ‘substantial decrease’ in mortality, trial shows | STAT | 11/27/2019

Regeneron Pharmaceuticals ( REGN ) and a single monoclonal antibody developed by the National Institute for Allergy and Infectious Diseases called mAb114 succumbed to their infections. The overall mortality rate in the outbreak, which enters its 17th month next week, stands at 67%. advertisement “It was a substantial decrease [in mortality],’’ said Dr. Anthony Fauci, director of NIAID, which designed and helped conduct the trial. “When you look at people who have …

George D. Yancopoulos

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | PR Newswire | 11/22/2019

TARRYTOWN, N.Y. Columbia’s highest honor bestowed for Yancopoulos’ contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded Columbia College’s Alexander Hamilton Medal , the highest honor awarded to a member of the Columbia College community for distinguished service and accomplishment in any field of endeavor. “George is a generational talent as a life …

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | BioSpace | 11/22/2019

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award Published: Nov 22, 2019 TARRYTOWN, N.Y. , Nov. 22, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. , (NASDAQ: REGN) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded Columbia College’s Alexander Hamilton Medal , the highest honor awarded to a member of the Columbia College community for distinguished service and accomplishment in any field of endeavor. “George is a …

Len Schleifer

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | PR Newswire | 11/22/2019

TARRYTOWN, N.Y. Columbia’s highest honor bestowed for Yancopoulos’ contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded … combined with his remarkably synergistic and long-term partnership with Len Schleifer , are the major drivers behind Regeneron’s extraordinary growth and contributions to human health over the years,” said Nobel Prize winner and Regeneron board …

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | BioSpace | 11/22/2019

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award Published: Nov 22, 2019 TARRYTOWN, N.Y. , Nov. 22, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. , (NASDAQ: REGN) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and … combined with his remarkably synergistic and long-term partnership with Len Schleifer , are the major drivers behind Regeneron’s extraordinary growth and contributions to human health over the years,” said Nobel Prize winner and Regeneron board …

Israel Lowy

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | PR Newswire | 11/22/2019

TARRYTOWN, N.Y. Columbia’s highest honor bestowed for Yancopoulos’ contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded … Development), who lead the Company’s regulatory and Global Development efforts; Israel Lowy , M.D., Ph.D. (Senior Vice President and Head of Translational Science and Oncology), who leads Regeneron’s clinical program in oncology; and Jay Markowitz , M.D …

Regeneron and Vyriad to develop oncolytic virus therapies | 11/7/2019

Regeneron Pharmaceuticals has formed a five-year alliance with Vyriad for the development of oncolytic virus-based treatments for cancer. Under the research collaboration and option licensing agreement, a clinical trial is set to be … anti-PD-1 activity. Regeneron Pharmaceuticals oncology senior vice-president Israel Lowy said: “We are eager to explore the combination of Voyager-V1 and Libtayo in patients with different tumour types in the short term …

Donald Trump

Justice Democrats Accuses Buttigieg of Abandoning Medicare for All After Taking ‘Tons of Cash’ From Corporate Interests | 11/13/2019

… Want It”—has received more campaign cash from the healthcare industry than any other 2020 presidential candidate aside from President Donald Trump. Shahid suggested Tuesday that industry cash played a role in Buttigieg’s decision to … insurance donations. His list of donors includes executives from Aetna, Regeneron Pharmaceuticals, Pfizer and Indiana’s Eli Lilly & Co. 9/19/2019 . Buttigieg shifts tactics and goes on the attack : “Anyone who lets the words Medicare for All …

Justice Democrats Accuses Buttigieg of Abandoning Medicare for All After Taking ‘Tons of Cash’ From Corporate Interests | Common Dreams News | 11/13/2019

… Want It”—has received more campaign cash from the healthcare industry than any other 2020 presidential candidate aside from President Donald Trump. Shahid suggested Tuesday that industry cash played a role in Buttigieg’s decision to … insurance donations. His list of donors includes executives from Aetna, Regeneron Pharmaceuticals, Pfizer and Indiana’s Eli Lilly & Co. 9/19/2019 . Buttigieg shifts tactics and goes on the attack : “Anyone who lets the words Medicare for All …

George Yancopoulos

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/6/2019

… source: The Motley Fool. Nov 05, 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Good morning, and welcome to the Regeneron Pharmaceuticals third-quarter 2019 earnings conference call. My name is Sheryl, and I will … Dr. Leonard Schleifer, founder, president and chief executive officer; Dr. George Yancopoulos, founding scientist, president and chief scientific officer; Marion McCourt, senior vice president and head of commercial; and Bob Landry, executive vice president and …

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/5/2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Justin Holko - VP, IR Len Schleifer - Co-Founder, President & CEO George Yancopoulos - Founding Scientist, President, Chief Scientific Officer & Director Marion McCourt - SVP & Head, Commercial Robert Landry - EVP, Finance & CFO Conference Call Participants Christopher Raymond - Piper Jaffray Companies Aaron Gal - Sanford C. Bernstein & Co. Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Porges …

J. Joseph Kim

Patients Turn to Advanced Technology in Order to Combat Cancer | PR Newswire | 11/6/2019

… INO-9012, an immune activator encoding IL-12, in combination with Libtayo® (cemiplimab), a PD-1 blocking antibody developed by Regeneron Pharmaceuticals (NASDAQ: REGN ) in collaboration with Sanofi. The data will be featured in a … first dose, substantially exceeding historical standard-of-care data. Dr. J. Joseph Kim , Inovio’s President & Chief Executive Officer, said, “Our new data demonstrates the potential of our immunotherapies utilizing tumor-associated antigens in cancer treatments …

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) | PR Newswire | 11/5/2019

… INO-9012, an immune activator encoding IL-12, in combination with Libtayo ® (cemiplimab), a PD-1 blocking antibody developed by Regeneron Pharmaceuticals (NASDAQ: REGN ) in collaboration with Sanofi. The data will be featured in a … meaningful benefit in this very difficult to treat disease.” Dr. J. Joseph Kim , Inovio’s President & CEO, said, “Our new data demonstrates the potential of our immunotherapies utilizing tumor-associated antigens in cancer treatments. Our goal …

Marion McCourt

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/6/2019

… source: The Motley Fool. Nov 05, 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Good morning, and welcome to the Regeneron Pharmaceuticals third-quarter 2019 earnings conference call. My name is Sheryl, and I will … Dr. George Yancopoulos, founding scientist, president and chief scientific officer; Marion McCourt, senior vice president and head of commercial; and Bob Landry, executive vice president and chief financial officer. After our prepared remarks, we will …

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/5/2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Justin Holko - VP, IR Len Schleifer - Co-Founder, President & CEO George Yancopoulos - Founding Scientist, President, Chief Scientific Officer & Director Marion McCourt - SVP & Head, Commercial Robert Landry - EVP, Finance & CFO Conference Call Participants Christopher Raymond - Piper Jaffray Companies Aaron Gal - Sanford C. Bernstein & Co. Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Porges …